Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Bedaquiline and Clarithromycin in Healthy Volunteers
NCT03800550Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2019
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bedaquiline in nontuberculous mycobacterial lung disease and Tuberculosis (TB) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Analyte Concentration of Bedaquiline and M2 at 240 hours, Minimum Observed Analyte Concentration of Bedaquiline and M2 at 240 hours and 2 more. Started Feb 2019; status: completed.
02
Drugs
bedaquiline
03
Conditions
nontuberculous mycobacterial lung diseaseTuberculosis (TB)
Beyond the preview
Go deeper on NCT03800550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03800550.